Publications
Cost-effectiveness of a 12-month fixed duration of Venetoclax in combination with Obinutuzumab versus chemoimmunotherapy and other novel combinations in first-line chronic lymphocytic leukemia in CanadaPublications
Explore the expertise, insights, and perspectives from OPEN Health that help transform complexity into clarity across today’s healthcare landscape.